Marwan G. Fakih, MD, City of Hope

Marwan G. Fakih, MD, is a professor in the Department of Medical Oncology & Therapeutics Research, associate director of Clinical Sciences, medical director of Briskin Center for Clinical Research, division chief of GI Medical Oncology, and co-director of the Gastrointestinal Cancer Program at City of Hope.

Articles

Unmet Needs in Third-Line mCRC: Challenges and Opportunities

December 12th 2024

Panelists discuss the most significant unmet needs in treating third-line metastatic colorectal cancer (mCRC), highlight areas where additional research is needed to improve patient outcomes, and explore investigational agents they find promising for future treatment options.

Dosing Trifluridine-Tipiracil (TAS-102) Plus Bevacizumab Considerations: Hepatic or Renal Impairment

December 12th 2024

Panelists discuss the frequency of hypertension observed with trifluridine-tipiracil plus bevacizumab and their strategies for monitoring and managing it, as well as their approach to dosing TAS-102 plus bevacizumab in patients with hepatic or renal impairment. They also review common toxicities associated with fruquintinib and regorafenib, including hypertension, hand-foot syndrome, and hepatotoxicity, and share management strategies for these adverse events.

Navigating Toxicities: Trifluridine-Tipiracil Plus Bevacizumab

December 5th 2024

Panelists discuss the common toxicities associated with trifluridine-tipiracil plus bevacizumab in clinical practice, including their typical severity, and share their strategies for managing dose reductions and interruptions due to cytopenias when treating patients with this regimen.

Factoring in Health-Related Quality of Life Outcomes in mCRC Treatment Selection

December 5th 2024

Panelists discuss how health-related quality of life (HRQOL) data influence their treatment decisions for third-line metastatic colorectal cancer (mCRC), how they assess patient symptoms and quality of life in clinical practice, and how the toxicity profiles of different therapies guide their treatment choices.

Perspectives on the SUNLIGHT Trial: Study Design and Outcomes

November 28th 2024

Panelists discuss their perspectives on the SUNLIGHT trial and how its active-arm comparator design, compared with placebo-controlled trials like FRESCO-2 and CORRECT, influences their treatment approach, while also exploring how specific efficacy outcomes impact their decision-making in third-line metastatic colorectal cancer.

Treatment Sequencing in mCRC: Balancing Expert Perspectives and Shared Decision-Making With Patients

November 28th 2024

Panelists discuss how patient preferences and lifestyle factors are considered when selecting between treatment options for third-line metastatic colorectal cancer (mCRC) and speak about their approaches to shared decision-making and optimal sequencing of therapies based on clinical context and patient needs.

Navigating mCRC: Treatment Options in the Third-Line Setting

November 21st 2024

Panelists discuss their preferred treatment options for patients in the third-line setting of metastatic colorectal cancer (mCRC), focusing on regorafenib, trifluridine-tipiracil plus bevacizumab, and fruquintinib, and share insights on how patient and disease-specific factors influence the selection of the most appropriate regimen for each clinical scenario.

Nuances With Defining “Refractory” mCRC in the Third-Line Setting

November 21st 2024

Panelists discuss how “refractory” metastatic colorectal cancer (mCRC) is defined in the third- vs fourth-line setting, and the treatment goals in the third-line setting, focusing on optimizing patient outcomes and managing progression after prior therapies.

Novel Approaches Under Study for Metastatic CRC

August 24th 2021

John L. Marshall, MD; Marwan G. Fakih, MD; and Joleen M. Hubbard, MD, highlight novel strategies in the metastatic colorectal cancer pipeline that look exciting and consider their integration into future clinical practice.

Treating Metastatic CRC With TKI/I-O Combinations

August 24th 2021

The rationale for continuing to study the combination of immunotherapies with novel tyrosine kinase inhibitors in metastatic colorectal cancer.

Metastatic CRC: Pembrolizumab Plus Lenvatinib

August 17th 2021

Implications for using the combination of pembrolizumab and lenvatinib to treat patients with metastatic colorectal cancer based on updated data from the LEAP-005 study.

Metastatic CRC: Nivolumab Plus Regorafenib

August 17th 2021

Considerations for treating patients with metastatic colorectal cancer with the combination of nivolumab and regorafenib based on preliminary data.

MSI-H Metastatic CRC: Chemo Vs I-O Debated

August 10th 2021

Drs. John L. Marshall, Marwan G. Fakih, and Joleen M. Hubbard, describe the current role of chemotherapy for frontline metastatic colorectal cancer based on novel treatment advances.

MSI-H Metastatic CRC: Frontline Immunotherapy

August 10th 2021

Considerations for frontline immunotherapy for patients with microsatellite instability high metastatic colorectal cancer based on data from the KEYNOTE-177 and CheckMate 142 studies.

Metastatic CRC: Frontline Therapy With EGFR Inhibitors

August 3rd 2021

Mayo Clinic’s Joleen M. Hubbard, MD, interprets data recently presented on the use of EGFR inhibitors as frontline therapy for appropriate patients with metastatic colorectal cancer.

MSS Metastatic CRC: First-Line Treatment Selection

August 3rd 2021

Tumor characteristics, patient factors, and supporting data that affect frontline treatment decisions for patients with microsatellite stable (MSS) metastatic colorectal cancer.

Molecular Markers and Tumor Sidedness in Metastatic CRC

July 27th 2021

Metastatic colorectal cancer (CRC) experts discuss tumor sidedness and their current use of next-generation sequencing panels to assess patients and guide treatment decisions.

Treatment Gaps for Patients With Metastatic CRC

July 27th 2021

Reactions to the increase in prevalence of metastatic colorectal cancer (CRC) among a younger patient population despite treatment advances.